Gabather AB (publ) (OM: GABA)
Health Care · Pharmaceuticals · SE
Skr0.03
-3.75% today · -28.9% 1Y
Gabather AB (publ) (OM: GABA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.06M and employs 2 people.
Over the last twelve months the share price has lost 28.9%, trading between 0.02 and 0.10.
Tweenvest scores Gabather AB (publ) across four factors: quality 21/100. Its strongest factor is quality.
GABA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.06M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- -0.77
- 52-week high
- Skr0.10
- 52-week low
- Skr0.02
- Avg volume (3M)
- —
- Shares outstanding
- 610.49M
- Employees
- 2
- Next earnings
- —
About Gabather AB (publ)
Gabather AB (publ) is dedicated to creating innovative pharmaceutical solutions for a range of central nervous system disorders. The company's focus includes developing medications for conditions such as psychotic illnesses, mood and anxiety disorders, pain relief, and cognitive function enhancement, notably those related to Alzheimer's disease. Founded in 2014, its operations are headquartered in Södertälje, Sweden.
- ISIN
- SE0010869552
- Founded
- 2014
- Listed since
- Nov 3, 2014
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.